Estrogen-Induced Activation of Erk-1 and Erk-2 Requires the G Protein-Coupled Receptor Homolog, GPR30, and Occurs via Trans-Activation of the Epidermal Growth Factor Receptor through Release of HB-EGF
The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Estrogen rapidly activates the mitogen-activated protein kinases, Erk-1 and Erk-2, via an as yet unknown mechanism. Here, evidence is provided that estrogen-induced Erk-1/-2 activation occurs independently of known estrogen receptors, but requires the expression of the G protein-coupled receptor homolog, GPR30. We show that 17beta-estradiol activates Erk-1/-2 not only in MCF-7 cells, which express both estrogen receptor alpha (ER alpha) and ER beta, but also in SKBR3 breast cancer cells, which fail to express either receptor. Immunoblot analysis using GPR30 peptide antibodies showed that this estrogen response was associated with the presence of GPR30 protein in these cells. MDA-MB-231 breast cancer cells (ER alpha-, ER beta+) are GPR30 deficient and insensitive to Erk-1/-2 activation by 17beta-estradiol. Transfection of MDA-MB-231 cells with a GPR30 complementary DNA resulted in overexpression of GPR30 protein and conversion to an estrogen-responsive phenotype. In addition, GPR30-dependent Erk-1/-2 activation was triggered by ER antagonists, including ICI 182,780, yet not by 17alpha-estradiol or progesterone. Consistent with acting through a G protein-coupled receptor, estradiol signaling to Erk-1/-2 occurred via a Gbetagamma-dependent, pertussis toxin-sensitive pathway that required Src-related tyrosine kinase activity and tyrosine phosphorylation of tyrosine 317 of the Shc adapter protein. Reinforcing this idea, estradiol signaling to Erk-1/-2 was dependent upon trans-activation of the epidermal growth factor (EGF) receptor via release of heparan-bound EGF (HB-EGF). Estradiol signaling to Erk-1/-2 could be blocked by: 1) inhibiting EGF-receptor tyrosine kinase activity, 2) neutralizing HB-EGF with antibodies, or 3) down-modulating HB-EGF from the cell surface with the diphtheria toxin mutant, CRM-197. Our data imply that ER-negative breast tumors that continue to express GPR30 may use estrogen to drive growth factor-dependent cellular responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor
Hanke, J. H., Gardner, J. P., Dow, R. L., Changelian, P. S., Brissette, W. H., Weringer, E. J., Pollok, B. A., & Connelly, P. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.2.695 · Cited by 1,939
Steroid hormone receptors: Many Actors in search of a plot
Beato, M., Herrlich, P., & Schütz, G. (1995) · Cell · doi:10.1016/0092-8674(95)90201-5 · Cited by 1,823
Tyrosine Kinase Inhibition: An Approach to Drug Development
Levitzki, A., & Gazit, A. (1995) · Science · doi:10.1126/science.7892601 · Cited by 1,635
Prenzel, N., Zwick, E., Daub, H., Leserer, M., Abraham, R., Wallasch, C., & Ullrich, A. (1999) · Nature · doi:10.1038/47260 · Cited by 1,504
Switching of the coupling of the β2-adrenergic receptor to different G proteins by protein kinase A
Daaka, Y., Luttrell, L. M., & Lefkowitz, R. J. (1997) · Nature · doi:10.1038/36362 · Cited by 1,270
Razandi, M., Pedram, A., Greene, G. L., & Levin, E. R. (1999) · Molecular Endocrinology · doi:10.1210/mend.13.2.0239 · Cited by 1,040
Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells.
Migliaccio, A., Di Domenico, M., Castoria, G., de Falco, A., Bontempo, P., Nola, E., & Auricchio, F. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00471.x · Cited by 959
Barkhem, T., Carlsson, B., Nilsson, Y., Enmark, E., Gustafsson, J.-Å., & Nilsson, S. (1998) · Molecular Pharmacology · doi:10.1124/mol.54.1.105 · Cited by 779
Aronica, S. M., Kraus, W. L., & Katzenellenbogen, B. S. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8517 · Cited by 670
Biscardi, J. S., Maa, M.-C., Tice, D. A., Cox, M. E., Leu, T.-H., & Parsons, S. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.12.8335 · Cited by 649
Research works printed but not linked: 5
- Adv Second Messenger Phosphoprotein Res, 31, 263
- Cieplak, 1987, Diphtheria toxin receptor: identification of specific diphtheria toxin-binding proteins on the surface of Vero and BS-C-1 cells., J Biol Chem, 262, 13246, 10.1016/S0021-9258(18)45193-9 · doi:10.1016/s0021-9258(18)45193-9
- Mukku, 1985, Regulation of epidermal growth factor receptor by estrogen., J Biol Chem, 260, 9820, 10.1016/S0021-9258(17)39309-2 · doi:10.1016/s0021-9258(17)39309-2
- Davidson, 1987, Epidermal growth factor receptor gene expresssion in estrogen receptor-positive and -negative human breast cancer cell lines., Mol Endocrinol, 1, 117, 10.1210/mend-1-3-216 · DOI
- Asslan, 1999, Epidermal growth factor stimulates 3-hydroxy-3-methylglutaryl-coenzyme A reductase expression via the ErbB-2 pathway in human breast adenocarcinoma cells., Biochem Biophys Res Commun, 260, 699, 10.1006/bbrc.1999.0945 · doi:10.1006/bbrc.1999.0945
Cited by
Items 101–108 of 108
The Neurosteroid Progesterone Underlies Estrogen Positive Feedback of the LH Surge
Micevych, P., & Sinchak, K. (2011) · Frontiers in Endocrinology · doi:10.3389/fendo.2011.00090 · Cited by 64
20-Hydroxyecdysone activates the protective arm of the RAAS via the MAS receptor
Lafont, R., Serova, M., Didry-Barca, B., Raynal, S., Guibout, L., Dinan, L., Veillet, S., Latil, M., Dioh, W., & Dilda, P. J. (2022) · Journal of Molecular Endocrinology · doi:10.1530/jme-21-0033 · Cited by 50
Sex-Specific Differences of the Inflammatory State in Experimental Autoimmune Myocarditis
Barcena, M. L., Jeuthe, S., Niehues, M. H., Pozdniakova, S., Haritonow, N., Kühl, A. A., Messroghli, D. R., & Regitz-Zagrosek, V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.686384 · Cited by 47
“Both ERK and p38 activation are modulated via ER activation (55) and play a crucial role in the polarization of pro-inflammatory macrophages (56).”
BackgroundThe role of G protein-coupled estrogen receptor 1 on neurological disorders
Roque, C., Mendes-Oliveira, J., Duarte-Chendo, C., & Baltazar, G. (2019) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2019.100786 · Cited by 41
Targeting the G protein-coupled estrogen receptor (GPER) in obesity and diabetes
Sharma, G., & Prossnitz, E. R. (2021) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2021.100080 · Cited by 34
“Furthermore, our studies in MIN6 cells revealed that GPER stimulates insulin release through intracellular calcium release and activation of ERK and PI3K pathways (Sharma and Prossnitz, 2011), with EGFR transactivation required for ERK activation, as reported in many cancer cells (Filardo et al., 2000; Sharma and Pros…”
BackgroundKanda, N., & Watanabe, S. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.23231.x · Cited by 29
G-protein αq participates in the steroid hormone 20-hydroxyecdysone nongenomic signal transduction
Ren, J., Li, X.-R., Liu, P.-C., Cai, M.-J., Liu, W., Wang, J.-X., & Zhao, X.-F. (2014) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2014.08.006 · Cited by 15
20-Hydroxyecdysone activates the protective arm of the renin angiotensin system via Mas receptor
Lafont, R., Raynal, S., Serova, M., Didry-Barca, B., Guibout, L., Latil, M., Dilda, P. J., Dioh, W., & Veillet, S. (2020) · doi:10.1101/2020.04.08.032607 · Cited by 11
Metadata
- Authors
- Filardo, E. J.
- Venue
- Molecular Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2000-10-01
- Volume
- 14
- Issue
- 10
- Pages
- 1649-1660
- ISSN
- 0888-8809 (ISSN-L)
- OpenAlex
- W2037790468
- Cited by
- 1,383
- References
- 48
- FWCI
- 15.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.